Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis
Article first published online: 31 AUG 2011
Copyright © 2011 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 63, Issue 9, pages 2567–2574, September 2011
How to Cite
Klein-Wieringa, I. R., van der Linden, M. P. M., Knevel, R., Kwekkeboom, J. C., van Beelen, E., Huizinga, T. W. J., van der Helm-van Mil, A., Kloppenburg, M., Toes, R. E. M. and Ioan-Facsinay, A. (2011), Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis & Rheumatism, 63: 2567–2574. doi: 10.1002/art.30449
- Issue published online: 31 AUG 2011
- Article first published online: 31 AUG 2011
- Accepted manuscript online: 12 MAY 2011 12:55PM EST
- Manuscript Accepted: 5 MAY 2011
- Manuscript Received: 13 DEC 2010
- TI Pharma (Top Institute Pharma, a public–private partnership, located in Leiden)
- European Union Sixth Framework Programme (AutoCure project)
- Seventh Framework Programme (Masterswitch project)
- Centre for Medical Systems Biology (grant within the framework of the Netherlands Genomics Initiative)
- The Netherlands Organization for Health Research and Development
Adipose tissue can secrete soluble mediators (adipokines) with potent immune regulatory functions. Some adipokines have been previously associated with radiographic damage in patients with rheumatoid arthritis (RA). In the present study, we investigated the capacity of baseline adipokine levels to predict radiographic progression over a period of 4 years and studied their contribution relative to that of other known risk factors, such as anti–cyclic citrullinated peptide (anti-CCP) antibodies.
Serum concentrations of leptin, visfatin, resistin, adiponectin, adipsin, tumor necrosis factor α (TNFα), and interleukin-6 (IL-6) were determined in serum samples obtained at baseline from 253 patients with RA from the Early Arthritis Cohort. The association between levels of these adipokines and radiographic progression was determined using a multivariate normal regression model correcting for age, sex, treatment strategy, body mass index (BMI), and the presence of anti-CCP antibodies.
Levels of IL-6, TNFα, visfatin, and adiponectin were positively associated with radiographic progression over 4 years. This association was independent of BMI. However, only adiponectin levels remained significantly associated with radiographic progression when the model was corrected for the presence of anti-CCP antibodies, whereas a trend was observed for IL-6. The association of both TNFα and visfatin with radiographic damage disappeared after correction for the presence of anti-CCP antibodies, which is consistent with the fact that the levels of both cytokines correlated significantly with anti-CCP antibody levels in these patients.
Our results indicate that adipokines are predictors of radiographic progression in RA, possibly through distinct underlying biologic mechanisms.